Investment Banking
Healthcare & Life Sciences

U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

Published on
September 17, 2018

Summary

Sebacia, Inc., a privately held, commercial stage dermatology andaesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has grantedclearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstratedclinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018.

Team Members Involved

Meet the talented individuals who brought their expertise and dedication to this project. Their collaboration, insight, and commitment to excellence were instrumental in delivering impactful results for our clients.

No team members are listed for this project.

Related News Articles

Stay updated with the latest industry news.

Related News Articles

Stay updated with the latest industry news.

Have questions? Our team is here to help

Whether you're seeking guidance on a complex transaction, exploring investment banking possibilities, or looking for wealth management strategies, our team is here to help.

Stay in touch

Provide your email to join our distribution list. By providing your email you consent to receive emails from Salem Partners Wealth Management.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.